Darren R. Feldman

1 month ago | urologytimes.com | Darren R. Feldman |Hannah Clarke

The phase 2 STARLITE 2 trial (NCT05239533) is assessing the safety and efficacy of 177Lu-girentuximab in combination with nivolumab for the treatment of patients with advanced clear cell renal cell carcinoma (ccRCC) that has the CAIX protein. In a recent interview with Urology Times®, Darren R.

Apr 16, 2024 | urologic.theclinics.com | Richard S. Matulewicz |Darren R. Feldman |Robert Hamilton

Keywords Testicular cancer Germ cell tumors miRNA Tumor markers Cisplatin-resistance Retroperitoneal lymph node dissection (RPLND) To read this article in full you will need to make a payment Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access One-time access price info For academic or personal research use, select 'Academic and Personal' For corporate R&D use, select 'Corporate R&D Professionals' Subscribers receive full online access to your...

Nov 10, 2023 | acsjournals.onlinelibrary.wiley.com | Deaglan J. McHugh |Jack Gleeson |Darren R. Feldman

INTRODUCTION Testicular cancers represent the most common malignancy affecting adolescent and young adult men in the United States, with roughly 9000 cases in the United States per year.1 The majority (>95%) of these cancers are germ cell tumors (GCTs) arising from primordial germ cells, which are the cells destined to become spermatozoa.